MAIA Biotechnology (MAIA) announced that independent directors including Adelina Louie Ngar Yee and Stan Smith, purchased common stock and warrants in the recent private placement offering which closed on December 22, 2025. Three directors purchased a total of 179,737 shares and 179,737 warrants with an average purchase price of $1.224. Dr. Smith has invested in all of MAIA’s funding rounds since the Company’s inception in 2018, and Adelina Louie is a top investor in MAIA. Gross proceeds from the offering totaled approximately $1.51M. To date, directors and officers hold 5,019,857 shares or 13.43% of MAIA.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology Announces $2.25M Private Placement Deal
- MAIA Biotechnology to sell 1.233M shares at $1.22 in private placement
- MAIA Biotechnology announces $1.51M private placement
- MAIA Biotechnology Announces Significant Insider Buying
- MAIA Biotechnology doses first patient in Phase 3 trial of ateganosine in NSCLC